Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Obesity Treatments

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

A government-funded bridge will preserve $50 access for beneficiaries.

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Novo Nordisk Launches Wegovy Weight-Loss Drug in India